Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ).
Cizzle Biotechnology Holdings PLC has signed a Letter of Intent with a leading UK clinical diagnostic group to verify and validate its CIZ1B biomarker test in partnership with the NHS. This agreement could lead to the group becoming the exclusive UK supplier of the test, aligning with Cizzle’s strategy to expand its early lung cancer detection services in the UK and Europe. The company has already secured a licensing agreement in North America and the Caribbean, and aims to support its US partner in obtaining CLIA accreditation. This move is part of Cizzle’s broader strategy to enhance early cancer detection globally, in line with NHS goals to improve cancer survival rates.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based diagnostics company focused on developing early cancer detection tests. The company’s primary product is the CIZ1B biomarker test, a non-invasive blood test for early-stage lung cancer detection, developed from pioneering research by Professor Dawn Coverley and her team at the University of York. Cizzle has entered into commercial licensing agreements and collaborations with cancer care centers and is listed on the London Stock Exchange.
Average Trading Volume: 1,463,715
Technical Sentiment Signal: Hold
Current Market Cap: £6.74M
Find detailed analytics on CIZ stock on TipRanks’ Stock Analysis page.